Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

RIGL Rigel Pharmaceuticals

1.180
-0.020-1.67%
Close 09/30 16:00 ET
1.230
+0.050+4.24%
Post Mkt Price 09/30 17:46 ET
High
1.260
Open
1.200
Turnover
1.71M
Low
1.180
Pre Close
1.200
Volume
1.41M
Market Cap
203.95M
P/E(TTM)
Loss
52wk High
3.620
Shares
172.84M
P/E(Static)
Loss
52wk Low
0.640
Float Cap
202.64M
Bid/Ask %
-33.33%
Historical High
114.750
Shs Float
171.73M
Volume Ratio
0.81
Historical Low
0.640
Dividend TTM
--
Div Yield TTM
--
P/B
-56.19
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.82%
Amplitude
6.67%
Avg Price
1.214
Lot Size
1
Float Cap
202.64M
Bid/Ask %
-33.33%
Historical High
114.750
Shs Float
171.73M
Volume Ratio
0.81
Historical Low
0.640
Dividend TTM
--
P/B
-56.19
Dividend LFY
--
Turnover Ratio
0.82%
Amplitude
6.67%
Avg Price
1.214
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
CEO: Mr. Raul R. Rodriguez
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...